Three-week pilot, randomised, double blind study of pexacerfont in patients with substance use disorder (amphetamine or opioid dependence)

Trial Profile

Three-week pilot, randomised, double blind study of pexacerfont in patients with substance use disorder (amphetamine or opioid dependence)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Pexacerfont (Primary)
  • Indications Substance withdrawal syndrome
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2017 New trial record
    • 23 Oct 2017 Primary endpoint of changes in the Visual Analog Scale (VAS) score for craving has been met, according to results published in the International Clinical Psychopharmacology.
    • 23 Oct 2017 Results published in the International Clinical Psychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top